Published in J Natl Cancer Inst on April 06, 1994
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol Cancer (2005) 1.40
TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. BMC Cancer (2016) 1.38
Retinoids: present role and future potential. Br J Cancer (1999) 1.28
Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett (2006) 1.13
Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol (2006) 1.11
Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer (2002) 0.95
Retinoic acid actions through mammalian nuclear receptors. Chem Rev (2013) 0.90
From Human Papillomavirus (HPV) Detection to Cervical Cancer Prevention in Clinical Practice. Cancers (Basel) (2014) 0.86
DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol (2011) 0.84
Suppression of growth by all-trans retinoic acid requires prolonged induction of interferon regulatory factor 1 in cervical squamous carcinoma (SiHa) cells. Clin Diagn Lab Immunol (2002) 0.84
Vaginal drug delivery for the localised treatment of cervical cancer. Drug Deliv Transl Res (2017) 0.83
Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes (2014) 0.81
Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis (1999) 0.80
Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol Oncol (2014) 0.78
Decreased serum retinol levels in women with cervical dysplasia. Br J Cancer (1996) 0.78
Cervical dysplasia regression induced by all-trans-retinoic acid. J Natl Cancer Inst (1994) 0.77
Therapeutic prevention of colorectal carcinogenesis. J Carcinog (2011) 0.77
No association between endogenous retinoic acid and human papillomavirus clearance or incident cervical lesions in Brazilian women. Cancer Prev Res (Phila) (2010) 0.77
Open questions in oesophageal adenocarcinogenesis. Gut (2007) 0.76
Cervical and Vulvar Intraepithelial Neoplasia after Treatment with Oral Isotretinoin for Severe Acne Vulgaris. Case Rep Dermatol (2009) 0.75
Medical treatment of cervical intraepithelial neoplasia II, III: an update review. Int J Clin Oncol (2009) 0.75
N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial. Invest New Drugs (2001) 0.75
A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med (1995) 6.14
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
Automated systems for identification of microorganisms. Clin Microbiol Rev (1992) 4.26
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
Role of solid media when used in conjunction with the BACTEC system for mycobacterial isolation and identification. J Clin Microbiol (1991) 3.60
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 2.90
Dematiaceous fungi are an increasing cause of human disease. Clin Infect Dis (1996) 2.72
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology (2009) 2.46
Bacterial population dynamics in three anopheline species: the impact on Plasmodium sporogonic development. Am J Trop Med Hyg (1996) 2.26
alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. Nature (1979) 2.25
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Colon cancer reduction. Questions about implementation of proven techniques. Arch Intern Med (1997) 2.12
Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem (1986) 2.05
Skin ulceration from extravasation of low-osmolality contrast medium: a complication of automation. AJR Am J Roentgenol (1992) 2.01
Increased incidence of Streptococcus agalactiae. Vet Rec (2002) 2.01
Urinary delta-aminolevulinic acid (ALA) levels in lead poisoning. I. A modified method for the rapid determination of urinary delta-aminolevulinic acid using disposable ion-exchange chromatography columns. Arch Environ Health (1967) 2.01
Telepathology overview: from concept to implementation. Hum Pathol (2001) 2.01
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med (1988) 1.94
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res (1995) 1.94
Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA (1991) 1.93
Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology (2001) 1.88
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev (2001) 1.87
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med (1982) 1.85
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
Plasmodium falciparum: inhibition of sporogonic development in Anopheles stephensi by gram-negative bacteria. Exp Parasitol (1993) 1.75
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med (1990) 1.72
Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol (2004) 1.70
Occupation, smoking, and alcohol in the epidemiology of bladder cancer. Am J Public Health (1987) 1.66
X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res (1995) 1.65
Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol (1993) 1.64
Effects of para-aminobenzoic acid, insulin, and gentamicin on Plasmodium falciparum development in anopheline mosquitoes (Diptera: Culicidae). J Med Entomol (1994) 1.61
Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg (1991) 1.60
Inherited predisposition to generalized amyloidosis. Clinical and pathological study of a family with neuropathy, nephropathy, and peptic ulcer. Neurology (1969) 1.58
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Rapid method for detection, identification, and susceptibility testing of enteric pathogens. J Clin Microbiol (1983) 1.54
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Clinical laboratory evaluation of a bacteriuria detection device for urine screening. Am J Clin Pathol (1984) 1.51
4-h Identification of Pseudomonas aeruginosa with 9-chloro-9-(4-diethylaminophenyl)-10-phenylacridan. J Clin Microbiol (1983) 1.50
Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs (1996) 1.49
Clinical laboratory evaluation of the automicrobic system Enterobacteriaceae biochemical card. J Clin Microbiol (1981) 1.48
Hematopathologic features of Epstein-Barr virus-induced human B-lymphoproliferation in mice with severe combined immunodeficiency. A model of lymphoproliferative diseases in immunocompromised patients. Lab Invest (1991) 1.48
Malaria infection potential of anopheline mosquitoes sampled by light trapping indoors in coastal Tanzanian villages. Med Vet Entomol (1995) 1.47
Analogues of amonafide and azonafide with novel ring systems. J Med Chem (2000) 1.47
Effect of beta-carotene on lymphocyte subpopulations in elderly humans: evidence for a dose-response relationship. Am J Clin Nutr (1991) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis (1994) 1.43
Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomarkers Prev (1999) 1.42
Correlation of DNA content and histology in prognosis of astrocytomas. Am J Clin Pathol (1988) 1.39
Arthroscopic partial medial meniscectomy: an analysis of unsatisfactory results. Arthroscopy (1985) 1.39
Transient stress lymphocytosis during crisis of sickle cell anemia and emergency trauma and medical conditions. An immunophenotyping study. Arch Pathol Lab Med (1990) 1.39
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology (1980) 1.37
Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev (1995) 1.36
Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res (2001) 1.35
Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood (1991) 1.35
Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol (2001) 1.34
Demographic and socioeconomic differences in beliefs about the health effects of smoking. Am J Public Health (1992) 1.34
Dynamic changes in prolactin promoter activation in individual living lactotrophic cells. Endocrinology (1998) 1.34
An analysis of occupational risks for brain cancer. Am J Public Health (1990) 1.31
Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol (1993) 1.31
Direct antimicrobial drug susceptibility testing of Mycobacterium tuberculosis by the radiometric method. Diagn Microbiol Infect Dis (1988) 1.30
In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (1980) 1.30
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture. In Vitro (1983) 1.29
Telepathology: a ten-year progress report. Hum Pathol (1997) 1.29
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis (1993) 1.28
1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res (1999) 1.27
Behavior problems in children at time of first recognized seizure and changes over the following 3 years. Epilepsy Behav (2011) 1.27
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Physical activity on the job and cancer in Missouri. Am J Public Health (1991) 1.26
Measurement of chemopreventive efficacy in skin biopsies. Anal Quant Cytol Histol (2001) 1.25
Photon correlation spectroscopy of hemoglobin: diffusion of oxy-HbA and oxy-HbS. Biopolymers (1978) 1.25
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 1.24
Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst (1994) 1.23
Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst (1992) 1.23
Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med (1997) 1.21
High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol (1981) 1.21
Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge. J Clin Invest (1992) 1.21
Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res (1997) 1.20
Karyometry in the early detection and chemoprevention of intraepithelial lesions. Eur J Cancer (2005) 1.20
Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol (1997) 1.20
Coping modeling problem solving versus mastery modeling: effects on adherence, in-session process, and skill acquisition in a residential parent-training program. J Consult Clin Psychol (1993) 1.20
Pharmacokinetics of very high-dose oral melphalan in cancer patients. Am J Clin Oncol (1990) 1.20
Malignant melanoma in southern Arizona. Increasing incidence and sunlight as an etiologic factor. Arch Dermatol (1981) 1.19
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem (2001) 1.19
Formation and alignment of Z lines in living chick myotubes microinjected with rhodamine-labeled alpha-actinin. J Cell Biol (1986) 1.19
Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden. Arch Dermatol (1978) 1.19
Epstein-Barr virus-associated lymphoproliferative disorders. Lab Invest (1992) 1.19